FTC Statement on Appellate Court Decision Ordering Delisting of Teva Inhaler Patents
December 20, 2024
December 20, 2024
WASHINGTON, Dec. 20 -- The Federal Trade Commission issued the following news release:
Today, the U.S. Court of Appeals for the Federal Circuit affirmed a lower district court order against pharmaceutical maker Teva requiring the drugmaker to delist several asthma inhaler patents from the Food and Drug Administration's (FDA) Orange Book.
The appellate court order stems from a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a . . .
Today, the U.S. Court of Appeals for the Federal Circuit affirmed a lower district court order against pharmaceutical maker Teva requiring the drugmaker to delist several asthma inhaler patents from the Food and Drug Administration's (FDA) Orange Book.
The appellate court order stems from a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a . . .